The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

References

• Johnson S, Smith A G, Loffler H, Osby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432–1438
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325
   PubMed Web of Science ®Google Scholar
• Eichhorst B F, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891
   PubMed Web of Science ®Google Scholar
• Byrd J C, Rai K, Peterson B L, Appelbaum F R, Morrison V A, Kolitz J E, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53
   PubMed Web of Science ®Google Scholar
• Tam C S, Keating M J, Wen S, Lerner S, Wierda W G, O'Brien S, et al. The Dominant Effect of Initial Treatment Regimen on the Survival of Patients with Chronic Lymphocytic Leukemia (CLL): An Analysis of 616 Patients Treated at the MD Anderson Cancer Center. Proc Haematol Soc Aust NZ Hobart 2006
   Google Scholar
• Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do K A, et al. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006; 106: 337–345
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Keating M J, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755–1762
   PubMed Web of Science ®Google Scholar
• Perkins J G, Flynn J M, Howard R S, Byrd J C. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033–2039
   PubMed Web of Science ®Google Scholar
• Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 2003; 30: 493–501
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, Broliden P A, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G, Leach M, Rassam S M, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971–2979
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Byrd J C, O'Brien S, Flinn I, Kipps T J, Weiss M A, Rai K, et al. Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2004; 104: 2503
   Google Scholar
• Keating M J, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Ferrajoli A, Faderl S, Koller C, Giles F, et al. Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. Blood 2005; 106: 213a, (Abstr #719)
   Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Wierda W, Tsimberidou A, O'Brien S, Ferrajoli A, Faderl S, Ravandi F, et al. The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's Transformation and FLU-refractory CLL. J Clin Oncol (Meeting Abstracts) 2006; 24: 6608
   Google Scholar
• Giles F J, O'Brien S M, Santini V, Gandhi V, Plunkett W, Seymour J F, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 1999; 36: 57–65
   PubMed Web of Science ®Google Scholar
• Seymour J F, Grigg A P, Szer J, Fox R M. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002; 94: 585–593
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Worth L J, Dooley M J, Seymour J F, Mileshkin L, Slavin M A, Thursky K A. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 2005; 92: 867–872
   PubMed Web of Science ®Google Scholar
• Khouri I F. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006; 390–397
   PubMedGoogle Scholar
• Khouri I F, Lee M S, Saliba R M, Andersson B, Anderlini P, Couriel D, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28–35
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K C, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343–5349
   PubMed Web of Science ®Google Scholar
• Byrd J C, Lin T S, Dalton J T, Wu D, Phelps M A, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399–404
   PubMed Web of Science ®Google Scholar
• Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez C O, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 2001; 19: 2142–2152
   PubMed Web of Science ®Google Scholar
• Bayes M, Rabasseda X, Prous J R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2006; 28: 185–206
   PubMedGoogle Scholar
• O'Brien S, Moore J O, Boyd T E, Larratt L M, Skotnicki A, Koziner B, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114–1120
   PubMed Web of Science ®Google Scholar